Ammar A, Schmidt A, Semmekrot B, Roseau S, Butlen D
Laboratoire de Physiologie Cellulaire, URA n.219 du CNRS, Collège de France, Paris.
Pflugers Arch. 1991 Apr;418(3):220-7. doi: 10.1007/BF00370519.
A microassay was developed to measure the binding of the labelled monoiodinated analogue [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid), 2-O-methyltyrosine, 4-threonine, 8-ornithine, 9-125I-tyrosylamide]vasotocin [125I-d(CH2)5[Tyr (Me)2, Thr4, Tyr-NH(2)9]OVT] to isolated nephron segments microdissected from collagenase-treated rat kidneys. When determined using 1.7 nM labelled ligand at 4 degrees C, specific binding sites (expressed at 10(-18) mol 125I-d(CH2)5[Tyr (Me)2, Thr4, Tyr-NH(2)9]OVT bound/mm tubule length) were found in medullary thick ascending limbs (MTAL), 1.67 +/- 0.49; cortical thick ascending limbs, 2.20 +/- 0.80; cortical collecting ducts, 2.39 +/- 0.86; outer medullary collecting ducts (OMCD), 2.54 +/- 0.53 and inner medullary collecting ducts, 5.33 +/- 0.40, whereas no specific binding could be detected in glomeruli and proximal tubules. Specific 125I-d(CH2)5[Tyr (Me)2, Thr4, Tyr-NH(2)9]OVT binding to OMCD was saturable with incubation time and reversible after elimination of free labelled ligand (the association and dissociation rate constants at 4 degrees C were 1.06 x 10(7) M-1 min-1 and 1.95 x 10(-2) min-1 respectively). The stereospecificity of MTAL and OMCD binding sites was assessed in competitive experiments revealing the following recognition pattern for a series of eight vasopressin analogues:dDAVP greater than AVP greater than d(CH2)5-[Tyr (Me)2, Thr4, Tyr-NH(2)9]OVT = AVT = OT greater than d(CH2)5[Tyr(Me)2]AVP = [Thr4, Gly7]OT greater than [Phe2, Orn8]VT, whereas pharmacological concentrations of insulin and glucagon did not impair radioligand binding. These results indicate that the detected labelled binding sites might correspond mainly to physiological V2 vasopressin receptors.
开发了一种微量分析法,用于测量标记的单碘化类似物[1-(β-巯基-β,β-环戊亚甲基丙酸),2-O-甲基酪氨酸,4-苏氨酸,8-鸟氨酸,9-125I-酪氨酰胺]血管升压素[125I-d(CH2)5[Tyr (Me)2, Thr4, Tyr-NH(2)9]OVT]与从胶原酶处理的大鼠肾脏中显微解剖分离的肾单位节段的结合。当在4℃下使用1.7 nM标记配体进行测定时,在髓质厚升支(MTAL)中发现特异性结合位点(以10(-18)mol 125I-d(CH2)5[Tyr (Me)2, Thr4, Tyr-NH(2)9]OVT结合/毫米肾小管长度表示),为1.67±0.49;皮质厚升支为2.20±0.80;皮质集合管为2.39±0.86;外髓集合管(OMCD)为2.54±0.53;内髓集合管为5.33±0.40,而在肾小球和近端小管中未检测到特异性结合。125I-d(CH2)5[Tyr (Me)2, Thr4, Tyr-NH(2)9]OVT与OMCD的特异性结合随孵育时间饱和,并且在去除游离标记配体后是可逆的(4℃下的缔合和解离速率常数分别为1.06×10(7)M-1分钟-1和1.95×10(-2)分钟-1)。在竞争性实验中评估了MTAL和OMCD结合位点的立体特异性,揭示了一系列八种血管加压素类似物的以下识别模式:dDAVP>AVP>d(CH2)5-[Tyr (Me)2, Thr4, Tyr-NH(2)9]OVT = AVT = OT>d(CH2)5[Tyr(Me)2]AVP = [Thr4, Gly7]OT>[Phe2, Orn8]VT,而药理浓度的胰岛素和胰高血糖素不损害放射性配体结合。这些结果表明,检测到的标记结合位点可能主要对应于生理性V2血管加压素受体。